Tetraspanin (TSP-17) Protects Dopaminergic Neurons against 6-OHDA-Induced Neurodegeneration in C. elegans

PLoS Genetics

Volumn 10, Issue 12, 2014, Pages

  Masoudi, Neda ^a,c   Ibanez Cruceyra, Pablo ^a,b   Offenburger, Sarah Lena ^a   Holmes, Alexander ^a   Gartner, Anton ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ECOLE NORMALE SUPÉRIEURE   (France)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; OXIDOPAMINE; PROTEIN TSP 17; TETRASPANIN; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAENORHABDITIS ELEGANS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXPERIMENTAL PARALYSIS; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; GENETIC MODEL; LARVAL STAGE; LOSS OF FUNCTION MUTATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NULL ALLELE; PARKINSON DISEASE; PHENOTYPIC PLASTICITY; PRESYNAPTIC NERVE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TSP 17 GENE; AMINO ACID SEQUENCE; ANIMAL; ANIMAL BEHAVIOR; CELL PROTECTION; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SEQUENCE HOMOLOGY; TRANSGENIC ORGANISM;

CAENORHABDITIS ELEGANS;

AMINO ACID SEQUENCE; ANIMALS; BEHAVIOR, ANIMAL; CAENORHABDITIS ELEGANS; CYTOPROTECTION; DOPAMINERGIC NEURONS; MOLECULAR SEQUENCE DATA; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; ORGANISMS, GENETICALLY MODIFIED; OXIDOPAMINE; SEQUENCE HOMOLOGY, AMINO ACID; TETRASPANINS;

EID: 84919629975     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004767     Document Type: Article

References (70)

1. Calne DB, Langston JW, (1983) Aetiology of Parkinson's disease. Lancet 2: 1457–1459.
2. Zigmond MJ, Burke RE, (2002) pathophysiology of parkinson's disease. Fifth generation of progess American college of Neuropsychopharmacology Williams and Wilkens 1781–1794.
3. Nass R, Hall DH, Miller DM, 3rdBlakely RD, (2002) Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America 99: 3264–3269.
4. Nass R, Blakely RD, (2003) The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annual review of pharmacology and toxicology 43: 521–544.
5. Chase TN, (1997) A gene for Parkinson disease. Archives of neurology 54: 1156–1157.
6. Lai CH, Chou CY, Ch'ang LY, Liu CS, Lin W, (2000) Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome research 10: 703–713.
7. Klein C, Westenberger A, (2012) Genetics of Parkinson's disease. Cold Spring Harbor perspectives in medicine 2: a008888.
8. Langston JW, Ballard P, Tetrud JW, Irwin I, (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.
9. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS, (2001) Environmental risk factors and Parkinson's disease: a metaanalysis. Environmental research 86: 122–127.
10. Tipton KF, Singer TP, (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of neurochemistry 61: 1191–1206.
11. Glinka Y, Gassen M, Youdim MB, (1997) Mechanism of 6-hydroxydopamine neurotoxicity. Journal of neural transmission Supplementum 50: 55–66.
12. Kostrzewa RM, Jacobowitz DM, (1974) Pharmacological actions of 6-hydroxydopamine. Pharmacological reviews 26: 199–288.
13. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, et al. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochemical research 18: 1175–1177.
14. Tieu K, (2011) A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor perspectives in medicine 1: a009316.
15. Fahn S, Cohen G, (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of neurology 32: 804–812.
16. Bove J, Perier C, (2012) Neurotoxin-based models of Parkinson's disease. Neuroscience 211: 51–76.
17. Birkmayer W, Hornykiewicz O, (1998) The effect of l-3,4-dihydroxyphenylalanine ( = DOPA) on akinesia in parkinsonism. Parkinsonism & related disorders 4: 59–60.
18. Cotzias GC, Papavasiliou PS, Gellene R, (1969) Modification of Parkinsonism–chronic treatment with L-dopa. The New England journal of medicine 280: 337–345.
19. Fahn S, (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Archives of neurology 56: 529–535.
20. White JG, Southgate E, Thomson JN, Brenner S, (1986) The structure of the nervous system of the nematode Caenorhabditis elegans. Philosophical transactions of the Royal Society of London Series B, Biological sciences 314: 1–340.
21. Brenner S, (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71–94.
22. Sulston J, Dew M, Brenner S, (1975) Dopaminergic neurons in the nematode Caenorhabditis elegans. The Journal of comparative neurology 163: 215–226.
23. Toth ML, Simon P, Kovacs AL, Vellai T, (2007) Influence of autophagy genes on ion-channel-dependent neuronal degeneration in Caenorhabditis elegans. Journal of cell science 120: 1134–1141.
24. Chen N, Reith ME, (2004) Interaction between dopamine and its transporter: role of intracellular sodium ions and membrane potential. Journal of neurochemistry 89: 750–765.
25. Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, et al. (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. The EMBO journal 26: 2127–2136.
26. Moszczynska A, Saleh J, Zhang H, Vukusic B, Lee FJ, et al. (2007) Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. Journal of molecular neuroscience: MN 32: 217–227.
27. Lee FJ, Liu F, Pristupa ZB, Niznik HB, (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 15: 916–926.
28. Chang MY, Lee SH, Kim JH, Lee KH, Kim YS, et al. (2001) Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein. Journal of neurochemistry 77: 754–761.
29. Vallone D, Picetti R, Borrelli E, (2000) Structure and function of dopamine receptors. Neuroscience and biobehavioral reviews 24: 125–132.
30. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG, (1998) Dopamine receptors: from structure to function. Physiological reviews 78: 189–225.
31. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC, (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151.
32. Beaulieu JM, Gainetdinov RR, (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological reviews 63: 182–217.
33. Allen AT, Maher KN, Wani KA, Betts KE, Chase DL, (2011) Coexpressed D1- and D2-like dopamine receptors antagonistically modulate acetylcholine release in Caenorhabditis elegans. Genetics 188: 579–590.
34. Zhou QY, Palmiter RD, (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83: 1197–1209.
35. Szczypka MS, Rainey MA, Palmiter RD, (2000) Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nature genetics 25: 102–104.
36. Sawin ER, Ranganathan R, Horvitz HR, (2000) C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26: 619–631.
37. McDonald PW, Hardie SL, Jessen TN, Carvelli L, Matthies DS, et al. (2007) Vigorous motor activity in Caenorhabditis elegans requires efficient clearance of dopamine mediated by synaptic localization of the dopamine transporter DAT-1. The Journal of neuroscience: the official journal of the Society for Neuroscience 27: 14216–14227.
38. Thompson O, Edgley M, Strasbourger P, Flibotte S, Ewing B, et al. (2013) The million mutation project: a new approach to genetics in Caenorhabditis elegans. Genome research 23: 1749–1762.
39. Boucheix C, Benoit P, Frachet P, Billard M, Worthington RE, et al. (1991) Molecular cloning of the CD9 antigen. A new family of cell surface proteins. The Journal of biological chemistry 266: 117–122.
40. Boucheix C, Duc GH, Jasmin C, Rubinstein E, (2001) Tetraspanins and malignancy. Expert reviews in molecular medicine 2001: 1–17.
41. Boucheix C, Rubinstein E, (2001) Tetraspanins. Cellular and molecular life sciences: CMLS 58: 1189–1205.
42. Rubinstein E, (2011) The complexity of tetraspanins. Biochemical Society transactions 39: 501–505.
43. Dunn CD, Sulis ML, Ferrando AA, Greenwald I, (2010) A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells. Proceedings of the National Academy of Sciences of the United States of America 107: 5907–5912.
44. Moribe H, Yochem J, Yamada H, Tabuse Y, Fujimoto T, et al. (2004) Tetraspanin protein (TSP-15) is required for epidermal integrity in Caenorhabditis elegans. Journal of cell science 117: 5209–5220.
45. Garcia-Espana A, Chung PJ, Sarkar IN, Stiner E, Sun TT, et al. (2008) Appearance of new tetraspanin genes during vertebrate evolution. Genomics 91: 326–334.
46. Cao S, Gelwix CC, Caldwell KA, Caldwell GA, (2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. The Journal of neuroscience: the official journal of the Society for Neuroscience 25: 3801–3812.
47. Jayanthi LD, Apparsundaram S, Malone MD, Ward E, Miller DM, et al. (1998) The Caenorhabditis elegans gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. Molecular pharmacology 54: 601–609.
48. Strange K, Christensen M, Morrison R, (2007) Primary culture of Caenorhabditis elegans developing embryo cells for electrophysiological, cell biological and molecular studies. Nat Protoc 2: 1003–1012.
49. Carvelli L, McDonald PW, Blakely RD, Defelice LJ, (2004) Dopamine transporters depolarize neurons by a channel mechanism. Proceedings of the National Academy of Sciences of the United States of America 101: 16046–16051.
50. Cass WA, Gerhardt GA, (1994) Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neuroscience letters 176: 259–263.
51. Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, et al. (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Molecular pharmacology 71: 1222–1232.
52. Thaminy S, Miller J, Stagljar I, (2004) The split-ubiquitin membrane-based yeast two-hybrid system. Methods Mol Biol 261: 297–312.
53. Rubinstein E, Le Naour F, Lagaudriere-Gesbert C, Billard M, Conjeaud H, et al. (1996) CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. European journal of immunology 26: 2657–2665.
54. Charrin S, le Naour F, Silvie O, Milhiet PE, Boucheix C, et al. (2009) Lateral organization of membrane proteins: tetraspanins spin their web. The Biochemical journal 420: 133–154.
55. Moribe H, Konakawa R, Koga D, Ushiki T, Nakamura K, et al. (2012) Tetraspanin is required for generation of reactive oxygen species by the dual oxidase system in Caenorhabditis elegans. PLoS genetics 8: e1002957.
56. Seeman P, (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4: 56–73.
57. Seeman P, (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 17: 118–132.
58. Rang HP, Dale MM, Ritter JM, Flower RJ, (2007) Antipsychotics drugs. Rang and Dale's Pharmacology 545–556.
59. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG, (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606–612.
60. Uhl GR, (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Annals of neurology 43: 555–560.
61. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG, (1998) Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 26: 148–153.
62. Ferris MJ, Calipari ES, Yorgason JT, Jones SR, (2013) Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices. ACS Chem Neurosci 4: 693–703.
63. Calipari ES, Ferris MJ, Salahpour A, Caron MG, Jones SR, (2013) Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun 4: 2720.
64. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB, (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. Journal of neural transmission Supplementum 46: 297–314.
65. LaVoie MJ, Hastings TG, (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. The Journal of neuroscience: the official journal of the Society for Neuroscience 19: 1484–1491.
66. Santiago M, Matarredona ER, Granero L, Cano J, Machado A, (2000) Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals. Brain research 858: 26–32.
67. Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, Daya S, (2005) l-DOPA administration enhances 6-hydroxydopamine generation. Brain research 1063: 180–186.
68. Galvin JE, (2006) Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 112: 115–126.
69. Davis MW, Hammarlund M, Harrach T, Hullett P, Olsen S, et al. (2005) Rapid single nucleotide polymorphism mapping in C. elegans. BMC Genomics 6: 118.
70. Chase DL, Pepper JS, Koelle MR, (2004) Mechanism of extrasynaptic dopamine signaling in Caenorhabditis elegans. Nature neuroscience 7: 1096–1103.